Grant: CIHR Fellowship
University of Toronto
$165,000.00
The surgical management of aortic valve disease in the era of transcatheter aortic valve replacement
FY 2017-18
Summary
Aortic stenosis (AS) is the most common acquired abnormality of the heart valves, affecting 10% of people over the age of 65. In AS, the movement of aortic valve leaflets is restricted, blocking blood flow from the heart to the rest of the circulation. In symptomatic people, up to 50% will die if left untreated. Historically, open heart surgery was required to remove the damaged aortic valve and replace it with an artificial valve, an invasive procedure suitable only for healthy elderly individuals. The durability of the valve replacement surgery depends on several factors, particularly, the patient's age and the type of artificial valve placed. Failing valve replacements traditionally required a second, higher risk open heart procedure. More recently, a minimally invasive technique called transcatheter aortic valve replacement (TAVR) has become the treatment of choice for patients at extreme surgical risk as well as many at moderate risk. In TAVR, blood vessels in the groin are accessed to replace the damaged heart valve. TAVR has emerged as a possible lower risk treatment for failed artificial valves. Nonetheless, in low risk and young patients, open heart surgery remains the standard treatment for AS. The goal of this research is to determine the ideal management of aortic valve disease with considerations for new minimally invasive approaches. First, we will address whether there have been changes in the types and sizes of aortic valves placed in young and low risk patients at the time of their open-heart surgery after the introduction of TAVR as this would affect their treatment options should their artificial valve fail. We will then determine the best treatment strategy for patients that previously had surgery but now have a failing replaced valve. Finally, we will determine the optimal management strategy for young and low risk patients through computer simulation models. There are currently no studies to inform the best treatment pathways for this group.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
377068
Name
Tam Derrick Yut-Ming
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Health systems / services
Prcname2
Health Research Training B - HP
Projecttitle
The surgical management of aortic valve disease in the era of transcatheter aortic valve replacement
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$165,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aortic Stenosis; Cost-Effectiveness; Transcatheter Valves
Abstract
Aortic stenosis (AS) is the most common acquired abnormality of the heart valves, affecting 10% of people over the age of 65. In AS, the movement of aortic valve leaflets is restricted, blocking blood flow from the heart to the rest of the circulation. In symptomatic people, up to 50% will die if left untreated. Historically, open heart surgery was required to remove the damaged aortic valve and replace it with an artificial valve, an invasive procedure suitable only for healthy elderly individuals. The durability of the valve replacement surgery depends on several factors, particularly, the patient's age and the type of artificial valve placed. Failing valve replacements traditionally required a second, higher risk open heart procedure. More recently, a minimally invasive technique called transcatheter aortic valve replacement (TAVR) has become the treatment of choice for patients at extreme surgical risk as well as many at moderate risk. In TAVR, blood vessels in the groin are accessed to replace the damaged heart valve. TAVR has emerged as a possible lower risk treatment for failed artificial valves. Nonetheless, in low risk and young patients, open heart surgery remains the standard treatment for AS. The goal of this research is to determine the ideal management of aortic valve disease with considerations for new minimally invasive approaches. First, we will address whether there have been changes in the types and sizes of aortic valves placed in young and low risk patients at the time of their open-heart surgery after the introduction of TAVR as this would affect their treatment options should their artificial valve fail. We will then determine the best treatment strategy for patients that previously had surgery but now have a failing replaced valve. Finally, we will determine the optimal management strategy for young and low risk patients through computer simulation models. There are currently no studies to inform the best treatment pathways for this group.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tam, Derrick Yut-Ming
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $165,000~ $0~